Aspira Women's Health Secures $1.0M High-Cost Subordinated Loan with Short Maturity
Summary
Aspira Women's Health secured a $1.0 million net proceeds subordinated term loan with a very high cost of capital and short maturity, indicating significant financial strain.
Key Events
-
Secured $1.05 Million Subordinated Term Loan
The company entered into a Subordinated Business Loan and Security Agreement for a principal amount of $1.05 million, with net proceeds of $1.0 million after a $50,000 administrative fee.
-
High Cost of Capital and Short Maturity
The loan includes substantial interest charges, leading to a total repayment of $1.491 million by the maturity date of August 26, 2026, reflecting a payment multiplier of 1.42 over approximately seven months.
-
Loan is Secured and Subordinated
The term loan is secured by a continuing security interest in substantially all of the company's and its co-borrowers' personal property and is expressly subordinated to all Senior Indebtedness.
-
Proceeds for General Corporate Purposes
The company intends to use the net proceeds from the loan for general corporate purposes, suggesting a need for operational liquidity.
Analysis
Aspira Women's Health Inc. has entered into a Subordinated Business Loan and Security Agreement for a $1.05 million term loan, providing net proceeds of $1.0 million for general corporate purposes. This financing is characterized by extremely high costs, with total repayments of $1.491 million over a short maturity period ending August 26, 2026, implying a payment multiplier of 1.42. The loan is secured by substantially all of the company's personal property and is expressly subordinated to existing senior indebtedness. This highly expensive, short-term debt, following a significant $10.0 million committed equity financing initiated on January 12, 2026, suggests the company is under considerable financial pressure and is resorting to costly measures to secure liquidity. The terms indicate a distressed financing scenario, raising concerns about the company's ongoing operational funding and long-term viability.
At the time of this filing, AWHL was trading at $0.48 on OTC in the Life Sciences sector, with a market capitalization of approximately $20.9M. The 52-week trading range was $0.02 to $0.71. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.